Sutro Biopharma ROE

Mitä Sutro Biopharma tekee? Sutro Biopharma Inc, listed on the stock market with the ticker STRO, is a biotechnology company based in South San Francisco, United States. The company focuses on the discovery, development, and manufacturing of pharmaceutical products. Sutro Biopharma went public through an IPO on September 27, 2018. It currently employs 137 full-time employees. The company utilizes a cell-free protein synthesis platform called XpressCF for creating protein therapeutics targeting cancer and autoimmune disorders. Sutro Biopharma designs therapeutics using various modalities, including cytokine-based immuno-oncology treatments, antibody-drug conjugates (ADCs), and bispecific antibodies. These therapeutics are developed for clinically validated targets. The company has product candidates STRO-001 and STRO-002. STRO-001 is an ADC targeting CD74 for the treatment of multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC targeting folate receptor-alpha (FolRa) for the treatment of ovarian and endometrial cancers. The XpressCF platform is used to optimize these candidates for therapeutic index by strategically placing linker-warheads within the antibody structure. The company's website is www.sutrobio.com. Sutro Biopharma on yksi Eurpooliin suosituimmista yhtiöistä.